Can a newer drug prevent spine fractures in acromegaly patients?

NCT ID NCT07179926

Recruiting now Disease control Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at whether the drug Pasireotide LAR can reduce the risk of spine fractures in people with acromegaly better than another drug, Pegvisomant. Acromegaly is a condition where too much growth hormone weakens bones, leading to painful fractures. Researchers will follow 120 patients for one year, comparing those on Pasireotide LAR to past data from patients on Pegvisomant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pasireotide LAR (a drug that lowers growth hormone and IGF-1 levels)
What this could lead to: If successful, this could show that Pasireotide LAR is better at preventing spine fractures in people with acromegaly than the current alternative, Pegvisomant.
What could go wrong: This is a relatively small, non-randomized study comparing a new group to past data, so results may not be definitive. The benefit may be modest or not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acromegaly Growth Hormone-Secreting Pituitary Adenoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACROMEGALY ACROMEGALY DUE TO PITUITARY ADENOMA

Contacts and locations

Locations

Fondazione Policlinico Universitario Agostino Gemelli IRCCS UOC Endocrinologia e Diabetologia
RECRUITING

Rome, RM, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.